Ann: COVID ARDS Trial Topline 60-Day Results, page-1574

Yes and be able to obtain access to REM-L for compassionate use for those, mostly fairly young, poor souls in icu right now in Australia with Covid.

Given Remestemcel-L was given ethics approval to be used in Australian hospitals in September last year for COVID-19 ARDS it would still be accessible through the TGA Special Access Scheme …. I guess it is up to people’s medical practitioners to make the application on their patients behalf ?


Melbourne, Australia; September 2, 2020 and New York; USA; September 1, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome (ARDS).


https://www.tga.gov.au/form/special-access-scheme

Special Access Scheme

The Special Access Scheme (SAS) allows certain health practitioners to access therapeutic goods (such as medicines, medical devices or biologicals) that are not included in the Australian Register of Therapeutic Goods (ARTG) for a single patient. Therapeutic goods that are not included in the ARTG (and are not otherwise exempt from being in the ARTG) are described by us as 'unapproved'